CMS Finalizes Rate Hike for BG Medicine's Galectin-3 Test | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that the Centers for Medicare and Medicaid Services have published the final determination of the 2014 Medicare national limitation amount for the company's galectin-3 test, arriving at a price of $30.01.

This is an increase over the test's 2013 national limitation of $17.80, and represents a win for BG Medicine, which had petitioned CMS for reconsideration of the 2013 determination.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.